Fig. 1

Enrolment flow chart. Representation of patients screening, inclusion and follow-up of the study. a Dihydroartemisinin–piperaquine. b Artemether–lumefantrine
Enrolment flow chart. Representation of patients screening, inclusion and follow-up of the study. a Dihydroartemisinin–piperaquine. b Artemether–lumefantrine